Percutaneous Ethanol Injection of Hyperfunctioning Thyroid Nodules: Long-Term Follow-Up in 125 Patients
- 1 March 2008
- journal article
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 190 (3) , 800-808
Abstract
OBJECTIVE. The purpose of this study was to assess the long-term efficacy of percutaneous ethanol injection (PEI) for the treatment of hyperfunctioning thyroid nodules. MATERIALS AND METHODS. One hundred twenty-five patients (88 women, 37 men; age range, 17–76 years; mean age, 53 years) with 127 hyperfunctioning thyroid nodules (volume, 1.2–90 mL; mean, 10.3 mL) were treated with PEI. There were 1–11 PEI sessions per patient (average, 3.9) performed, with injection of 1–14 mL of ethanol per session (total injected ethanol per patient, 3–108 mL; mean, 14.0 mL). Efficacy of the treatment was assessed with color Doppler sonography; scintigraphy; and free triiodothyronine (FT3), free thyroxine (FT4), and thyroid-stimulating hormone (TSH) assays. Follow-up (9–144 months; median, 60 months) was performed with TSH and color Doppler sonography every 2 months for 6 months and every 6 months thereafter. RESULTS. Three (2.4%) of 125 patients refused completion of PEI therapy because of pain. Results are reported in 122 patients with 124 nodules. All 122 patients showed posttreatment normal levels of FT3, FT4, and TSH. A complete cure (absent uptake in the nodule and recovery of normal uptake in the thyroid parenchyma) was obtained in 113 (93%) of 122 patients—115 (92.7%) of 124 treated nodules. Residual hyperfunctioning nodular tissue along with decreased thyroid parenchyma uptake (partial cure) was present in nine patients accounting for nine (7.3%) of 124 nodules. Rates of complete cure after PEI were: overall nodules, 115 (92.7%) of 124; nodules ≤ 10 mL, 63 (94.0%) of 67; nodules > 10 to ≤ 30 mL, 32 (91.4%) of 35; nodules > 30 to ≤ 60 mL, 17 (89.5%) of 19; nodules > 60 mL, three (100%) of three. The overall rate of major complications (transient laryngeal nerve damage, two patients; abscess and hematoma, one patient each) was four (3.2%) of 125 patients. Follow-up examinations showed marked shrinkage of 112 treated nodules ranging from 50% to 90% of the pretreatment volume (mean, 66%) and new growth of hyperfunctioning tissue in four patients at color Doppler sonography and scintigraphy at 12, 18, 18, and 48 months' follow-up, respectively. However, all patients remained euthyroid (low or normal TSH and normal FT3 and FT4) during follow-up. CONCLUSION. PEI of hyperfunctioning thyroid nodules seems to be an effective and safe alternative to traditional treatment. It also appears to be effective in patients with hyperfunctioning thyroid nodules larger than 30 mL.Keywords
This publication has 22 references indexed in Scilit:
- Treatment of the autonomous thyroid nodule: a reviewEuropean Journal of Endocrinology, 1996
- Treatment of solitary autonomous thyroid nodules by percutaneous ethanol injection: results of an Italian multicenter study. The Multicenter Study GroupThe Journal of Clinical Endocrinology & Metabolism, 1996
- Treatment of autonomous thyroid nodules: value of percutaneous ethanol injection.American Journal of Roentgenology, 1995
- Treatment of autonomous thyroid nodules with percutaneous ethanol injection: 4-year experience.Radiology, 1994
- Management of a Solitary Thyroid NoduleNew England Journal of Medicine, 1993
- Percutaneous ultrasound-guided ethanol injection: a new treatment of toxic autonomously functioning thyroid nodules?The Journal of Clinical Endocrinology & Metabolism, 1993
- Percutaneous intranodular ethanol injection: A new treatment for autonomous thyroid adenomaJournal of Endocrinological Investigation, 1992
- Treatment of autonomous thyroid nodules with percutaneous ethanol injection: preliminary results. Work in progress.Radiology, 1990
- Current Management of the Patient with Autonomously Functioning Nodular GoiterSurgical Clinics of North America, 1987
- Evolution of Toxicity in Solitary Nontoxic Autonomously Functioning Thyroid NodulesThe Journal of Clinical Endocrinology & Metabolism, 1980